Possible role of Helicobacter pylori infection via microvascular dysfunction in cardiac syndrome X by Rasmi, Yousef & Raeisi, Sina
www.cardiologyjournal.org 585
POINT OF VIEW
Cardiology Journal
2009, Vol. 16, No. 6, pp. 585–587
Copyright © 2009 Via Medica
ISSN 1897–5593
Address for correspondence:  Yousef Rasmi, Department of Biochemistry, Faculty of Medicine, Urmia University of Medical
Sciences, Urmia, Iran, tel: +984412770698, fax: +984412780801, e-mail: rasmiy@umsu.ac.ir
Received: 29.09.2009 Accepted: 18.10.2009
Possible role of Helicobacter pylori infection via
microvascular dysfunction in cardiac syndrome X
Yousef Rasmi, Sina Raeisi
Department of Biochemistry, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
Abstract
Recently, some investigators have reported seeing microvascular dysfunction in patients with
cardiac syndrome X (CSX). In addition, Helicobacter pylori (H. pylori), a bacterium cau-
sing chronic gastritis and peptic ulcers, has recently been associated with CSX. Yet the
mechanism(s) by which H. pylori infection leads to CSX is poorly understood. We propose
a link between H. pylori and microvascular dysfunction infection in the development of CSX.
(Cardiol J 2009; 16, 6: 585–587)
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Introduction
Cardiac syndrome X (CSX) is a condition char-
acterized by the presence of angina pectoris and
a positive response to stress or radionuclide tests
(thallium scan) with a normal coronary arteriogram
[1]. It is found in up to 20% of angina patients un-
dergoing angiography [2]. The varied pathogenic
mechanisms responsible for the condition, and the
varying diagnostic criteria used by different inves-
tigators, have helped complicate the diagnosis and
management of CSX patients [3].
H. pylori and inflammation
Previous studies have shown an association
between viral and bacterial infections (such as Heli-
cobacter pylori [H. pylori] infection) with vascular
diseases such as ischemic heart disease and CSX [4].
H. pylori is a gram-negative bacterium which infects
the human stomach [5], may cause extra-intestinal
manifestations some of which are functional ischem-
ic heart disease andrespiratory system disease
[6, 7], and has recently been associated with CSX [2].
Infection with H. pylori may be associated with sys-
temic and vascular inflammation. Prevalence of sero-
positivity to H. pylori significantly increases in sub-
jects with high sensitive C reactive protein (CRP),
a sensitive marker of systemic inflammation. Fur-
thermore, serum CRP levels positively correlate
with anti-H. pylori antibody titer levels.
Therefore, chronic infection with H. pylori may
account for, at least in part, the elevated serum CRP
level [7]. Chronic infection of H. pylori is most pro-
bably the cause of increased production of various
inflammatory metabolites, such as interlukin-1,
interleukin-6 and tumor necrosis factor-alpha which
also affect blood vessel motility and induce endothe-
lial dysfunction [8]. It has been shown that H. py-
lori induces gastric mucosal injury and inflamma-
tion that might be caused by the oxidant-mediated
expression of inflammatory cytokines, and inflam-
matory enzymes [9, 10]. Systemic inflammatory
reaction can be detected by showing increased plas-
ma levels of different pro-inflammatory cytokines
and acute-phase proteins which then may lead to
several diseasessuch as CSX [11]. A circulating
soluble form of intercellular adhesion molecule-1
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(ICAM-1), which is expressed on the activated en-
dothelium in response to inflammatory cytokines,
also was elevated in subjects positive to anti-H. py-
lori. Moreover, a previous study showed that
H. pylori eradication was associated with a significant
reduction in serum CRP levels and a significant rise
in serum HDL-cholesterol [12].
Inflammation and endothelial dysfunction
On the other hand, many observational stud-
ies have indicated that an elevated level of CRP is
independently associated with future risk of coro-
nary heart disease and stroke [13], supporting the
hypothesis that inflammation plays an important
role in the pathogenesis of atherosclerosis [14].
Recent observations suggest a role of inflam-
mation in the pathogenesis of endothelial dysfunc-
tion [15] and correlation of CRP-concentration with
severity of symptoms in patients with CSX [16].
The potential importance of inflammation in the
pathogenesis of CSX is highlighted by the benefi-
cial effects observed with the use of statins and
angiotensin- converting- enzyme inhibitors in pa-
tients with CSX [17]. Chronic inflammation leads
to an increase in the generation of pro-inflammato-
ry cytokines, cell adhesion molecules, and growth
factors that can elicit inflammatory and proliferative
changes in the vessel walls, resulting in endothe-
lial dysfunction [18]. Leukocyte binding to cellular
adhesion molecules on the surface of vascular en-
dothelium in response to many inflammatory cy-
tokines and CRP may be the earliest event in a vas-
cular inflammatory process [14].
Endothelial dysfunction
and microvascular dysfunction
CSX encompasses several possible causal
mechanisms. Cardiac and non-cardiac mechanisms
have been proposed, among which ‘endothelial dys-
function’ of the coronary microcirculation features
prominently [19]. According to the response-to-in-
jury hypothesis of atherosclerosis, endothelial dys-
function is the first step in atherosclerosis [14]. This
hypothesis has been supported by many studies,
indicating that endothelial dysfunction occurs in
subjects with classic risk factors such as hyperten-
sion, diabetes mellitus, hypercholesterolemia, and
smoking [20]. The mechanisms responsible for en-
dothelial dysfunction in CSX patients are not well
understood but risk factors such as obesity, hyper-
tension, hypercholesterolemia, diabetes, hyperho-
mocysteinemia and smoking may play a role [11].
Moreover, plasma levels of circulating ICAM-1 and
vascular adhesion molecule-1 are increased in pa-
tients with CSX, suggesting endothelial cell activa-
tion [11, 21]. Also, increased plasma concentration
of the powerful vasoconstrictor endothelin-1 (ET-1)
has been reported in peripheral blood of CSX pa-
tients and has been shown to correlate with en-
dothelial dysfunction; moreover, ET-1 has been
found to increase the coronary circulation of pa-
tients with CSX during arterial pacing [15].
On the other hand, CRP levels are known to
be associated with endothelial cell activation and
coronary endothelial dysfunction [22]. Reduced ni-
tric oxide bioavailability due to endothelial dysfunc-
tion [23] and enhanced ET-1 expression, promoted
by raised CRP levels [24], may be implicated in
systematic endothelial vasoreactivity leading to
microvascular angina [25, 26]. Several studies have
shown that patients with CSX have coronary micro-
vascular abnormalities [15]. Both vasodilator stim-
uli and vasoconstrictor stimuli have been used to
assess coronary microvascular function in patients
with CSX. The study of vasodilator function has
further concerned the assessment of endothelium-
dependent and endothelium-independent mecha-
nisms. Thus, endothelial function has an important
role in microvascular function [15]; and coronary
endothelial dysfunction leading to microvascular
angina has been proposed as a pathogenic mecha-
nism in CSX [11, 25, 26]. Endothelium-dependent
coronary microvascular function has mainly been
studied by assessing the coronary blood flow re-
sponse to acetylcholine, the vasodilator effect of
which is mediated by nitric oxide release by en-
dothelial cells [15, 23]. Some studies have shown
reduced endothelium-dependent vasodilatation or
increased vasoconstriction (or both) in response to
various stimuli such as exercise in epicardial coro-
nary artery vessels of patients with CSX [15].
Hypothesis
Due to the factors that occur secondary to
H. pylori infection, we speculate that H. pylori may
also cause endothelial dysfunction directly by affect-
ing the structure and function of vascular endothe-
lial cells via inflammation.
H. pylori may cause endothelial dysfunction.
H. pylori infection causes chronic inflammation and
increases the generation of pro-inflammatory cy-
tokines, cell adhesion molecules, growth factors and
acute-phase proteins. An increase in these factors
may affect vessel motility and can elicit inflamma-
tory and proliferative changes in the vessel walls
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(microvascular dysfunction) via endothelial dysfunc-
tion (Fig. 1).
In conclusion, we hypothesize that H. pylori
infection can be a trigger for the probable mecha-
nism of endothelial dysfunction via chronic inflam-
mation in the pathogenesis of CSX.
Since endothelial dysfunction is the trigger
point for many diseases, we must pay more atten-
tion to the diagnosis and treatment of H. pylori.
H. pylori may be the cause of, or at least one of the
leading factors in, many other diseases. To address
this hypothesis, further prospective studies are
warranted to evaluate the role of H. pylori eradica-
tion on endothelial function.
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Figure 1. Scheme of the hypothesis based on the main
pathogenic mechanisms and functional abnormalities
that may contribute to microvascular dysfunction in pa-
tients with cardiac syndrome X.
